文献速递药物相互作用特殊人群用药

巴西跨性别女性使用HIV暴露前预防时雌二醇与螺内酯的药代动力学潜在相互作用分析

Estradiol and Spironolactone Plasma Pharmacokinetics Among Brazilian Transgender Women Using HIV Pre-Exposure Prophylaxis: Analysis of Potential Interactions.
PubMed 文献 · Clin Pharmacokinet · 2023-06-01

该研究在19名巴西跨性别女性中开展药物相互作用亚研究,比较启动每日口服替诺福韦/恩曲他滨暴露前预防前后雌二醇和螺内酯的药代动力学。结果显示雌二醇AUCτ和 trough 浓度无显著变化,螺内酯及坎利酮AUCτ在启动暴露前预防后略有降低,但作者认为这些差异不应妨碍两者联用。

要点

  • 雌二醇药代动力学未受暴露前预防显著影响。
  • 螺内酯及坎利酮AUCτ在暴露前预防后轻度降低。
  • 小差异不应妨碍雌二醇基础激素治疗与暴露前预防联用。

核心结论

  • 雌二醇药代动力学不受暴露前预防联用影响,螺内酯和坎利酮药代动力学有小差异但不妨碍联用。

研究设计与样本

  • 在参加每日口服暴露前预防示范研究(PrEParadas, NCT03220152)的巴西跨性别女性中开展药物相互作用亚研究。
  • 参与者启动雌二醇戊酸酯2-6 mg联合螺内酯100-200 mg后15天进行首次药代动力学评估(PK1),随后启动替诺福韦二吡呋酯300 mg/恩曲他滨200 mg暴露前预防。
  • 12周后进行第二次药代动力学评估(PK2),直接观察给药前后采集血样(0、0.5、1、2、4、6、8和24小时)。
  • 采用非房室分析(Monolix 2021R2, Lixoft®)估计雌二醇、螺内酯及代谢物的药代动力学参数,以几何均值比(GMR,90%置信区间[CI])比较。
  • 19名完成亚研究的跨性别女性中位年龄26岁(四分位距:23-27.5)。

主要发现

  • 雌二醇AUCτ和 trough 浓度在PK1与PK2之间无差异(GMR [90% CI]:0.89 [0.76-1.04]和1.06 [0.94-1.20])。
  • 螺内酯和坎利酮AUCτ在PK2较PK1统计学降低(0.76 [0.65-0.89]和0.85 [0.78-0.94])。
  • 坎利酮最大浓度在PK2也较PK1降低(0.82 [0.74-0.91])。

关键数值与推荐

  • 雌二醇AUCτ的GMR为0.89(90% CI 0.76-1.04), trough 浓度GMR为1.06(90% CI 0.94-1.20)。
  • 螺内酯AUCτ的GMR为0.76(90% CI 0.65-0.89),坎利酮AUCτ的GMR为0.85(90% CI 0.78-0.94)。
  • 坎利酮最大浓度的GMR为0.82(90% CI 0.74-0.91)。

临床怎么用

  • 基于雌二醇药代动力学无显著变化,雌二醇基础激素治疗可与每日口服暴露前预防联用。
  • 螺内酯和坎利酮药代动力学的小差异不应成为联用暴露前预防的阻碍。

局限性

  • 研究样本量较小(19名完成亚研究)。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: An important barrier to HIV prevention among transgender women (TGW) is the concern that oral pre-exposure prophylaxis (PrEP) negatively affects the efficacy of feminizing hormone therapy (FHT). We aimed to assess the impact of PrEP on FHT pharmacokinetics (PK) among TGW from Brazil. METHODS: We performed a drug-drug interaction sub-study among TGW enrolled in a daily oral PrEP demonstration study (PrEParadas, NCT03220152). Participants had a first PK assessment (PK1) 15 days after FHT (estradiol valerate 2-6 mg plus spironolactone 100-200 mg) initiation and then started PrEP (tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg). A second PK evaluation was performed 12 weeks later (PK2). Blood samples were collected prior and after the directly observed dosing (0, 0.5, 1, 2, 4, 6, 8, and 24 hours). Pharmacokinetic parameters of estradiol, spironolactone, and metabolites were estimated by non-compartmental analysis (Monolix 2021R2, Lixoft®) and compared as geometric mean ratios (GMRs, 90% confidence interval [CI]). RESULTS: Among 19 TGW who completed the substudy, median age was 26 years (interquartile range: 23-27.5). Estradiol area under the plasma concentration-time curve (AUCτ) and trough concentrations did not differ between PK1 and PK2 evaluations (GMR [90% CI]: 0.89 [0.76-1.04] and 1.06 [0.94-1.20], respectively). Spironolactone and canrenone AUCτ were statistically lower at PK2 than PK1 (0.76 [0.65-0.89] and 0.85 [0.78-0.94], respectively). Canrenone maximum concentration was also lower at PK2 than PK1 (0.82 [0.74-0.91]). CONCLUSION: Estradiol PK was not influenced by PrEP concomitant use. The small differences observed in some spironolactone and canrenone PK parameters should not prevent the concomitant use of estradiol-based FHT and PrEP. TRIAL REGISTRATION: This trial (NCT03220152) was registered on July 18, 2017.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Cattani VB, Jalil EM, Eksterman L, et al. Estradiol and Spironolactone Plasma Pharmacokinetics Among Brazilian Transgender Women Using HIV Pre-Exposure Prophylaxis: Analysis of Potential Interactions. Clin Pharmacokinet. 2023. PMID: 37261664. doi:10.1007/s40262-023-01248-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。